Pfizer Inc. (NYSE:PFE) Shares Acquired by Generali Investments Towarzystwo Funduszy Inwestycyjnych

Generali Investments Towarzystwo Funduszy Inwestycyjnych grew its stake in Pfizer Inc. (NYSE:PFE) by 205.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 44,900 shares of the biopharmaceutical company’s stock after acquiring an additional 30,200 shares during the quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych’s holdings in Pfizer were worth $1,191,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Swedbank AB increased its position in shares of Pfizer by 0.7% during the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after purchasing an additional 37,636 shares during the last quarter. Pallas Capital Advisors LLC increased its position in shares of Pfizer by 54.8% during the 3rd quarter. Pallas Capital Advisors LLC now owns 25,711 shares of the biopharmaceutical company’s stock worth $736,000 after purchasing an additional 9,102 shares during the last quarter. Fidelis Capital Partners LLC increased its position in shares of Pfizer by 5.2% during the 3rd quarter. Fidelis Capital Partners LLC now owns 25,835 shares of the biopharmaceutical company’s stock worth $746,000 after purchasing an additional 1,267 shares during the last quarter. Great Diamond Partners LLC purchased a new position in Pfizer during the 3rd quarter valued at about $203,000. Finally, First Trust Direct Indexing L.P. boosted its holdings in Pfizer by 15.4% during the 3rd quarter. First Trust Direct Indexing L.P. now owns 82,585 shares of the biopharmaceutical company’s stock valued at $2,390,000 after acquiring an additional 11,026 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 1.3 %

Pfizer stock opened at $26.09 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company has a market cap of $147.83 billion, a PE ratio of 18.50, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The stock’s 50 day moving average price is $26.35 and its 200 day moving average price is $27.35.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.10 earnings per share. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.59%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s payout ratio is presently 121.99%.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

Analyst Ratings Changes

PFE has been the subject of a number of research analyst reports. Wolfe Research initiated coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price for the company. Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Citigroup decreased their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Finally, Guggenheim reiterated a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.